Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDSC for Diabetic Foot Ulcers and Neuropathy
NCT06373809Phase 1Completed
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of placenta-derived stem cells in diabetic foot ulcer (DFU) and diabetic neuropathy. Primary endpoint: Foot Ulcer Healing at 12 months. Started Oct 2021; status: completed.
02
Drugs
placenta-derived stem cells
03
Conditions
diabetic foot ulcer (DFU)diabetic neuropathy
Beyond the preview
Go deeper on NCT06373809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373809.